A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
Phase 3
Active, not recruiting
- Conditions
- Human Papillomavirus Infection
- Interventions
- Biological: Nonavalent HPV study vaccineBiological: GARDASIL® 9
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 1260
- Registration Number
- NCT06207175
- Locations
- 🇮🇩
University of Muhammadiyah Malang Hospital, Malang, Indonesia
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Phase 2
Completed
- Conditions
- Human Papilloma Virus Infection
- Interventions
- Biological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 780
- Registration Number
- NCT05694728
- Locations
- 🇨🇳
CDC, Jiangsu Province, Nanjing, Jiangsu, China
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Phase 1
Completed
- Conditions
- Human Papillomavirus Infection
- Interventions
- Biological: Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) VaccineBiological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 160
- Registration Number
- NCT05680454
- Locations
- 🇨🇳
CDC, Jiangsu Province, Nanjing, Jiangsu, China
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
Phase 3
Active, not recruiting
- Conditions
- Human Papillomavirus Infection
- Interventions
- Biological: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 12000
- Registration Number
- NCT05668572
- Locations
- 🇨🇳
CDC, Guangdong Provinc, Guangzhou, Guangdong, China
🇨🇳CDC, Jiangsu Province, Nanjing, Jiangsu, China
🇨🇳CDC, Shanxi Province, Taiyuan, Shanxi, China
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Phase 3
Active, not recruiting
- Conditions
- Human Papillomavirus Infection
- Interventions
- Biological: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)Biological: GARDASIL® 9
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Beijing Health Guard Biotechnology, Inc
- Target Recruit Count
- 2750
- Registration Number
- NCT05662020
- Locations
- 🇨🇳
Yunnan Center for Disease Prevention and Control, Kunming, Yunnan, China
© Copyright 2025. All Rights Reserved by MedPath